The concern of generic challenges has repeatedly loomed around copyright’s famous drug, Sildenafil, sparking questions about the outlook of related medicinal holdings. While first years saw impressive profits, the intellectual property expiration has opened the way for cheaper alternatives, likely diminishing revenue and creating a genuine hazard